TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02199041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given by intravenous infusion as part of the preparative regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given by intravenous infusion as part of the preparative regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given either by intravenous infusion or subcutaneously daily until absolute neutrophil count (ANC) \>2000 for 3 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given either intravenously or orally, if needed to treat graft-versus-host-disease (GVHD).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation
Description: TLI will be administered in divided fractions given at a minimum of 6 hours apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lymphocyte infusions
Description: Donors will undergo haploidentical mobilization with G-CSF. Cells will be collected by leukapheresis over two days, then processed using the investigational CliniMACS device and CD34 Microbead reagent as directed by the manufacturer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Study: NCT04462601

Intervention type: OTHER
Intervention: Biomarker detection
Description: Quantification of serum markers of intestinal permeability and bacterial and fungal translocation
Study: NCT03836443

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: western diet meal
Description: A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: western diet meal
Description: A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast.
Study: NCT00403130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles
Study: NCT04617080

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SUPRACOR Regular
Description: SUPRACOR algorithm with regular (100%) ablation profile. SUPRACOR is a presbyopic algorithm that consists of a pre-calculated pulse pattern combined to the refractive pattern to combine near, intermediate and distance vision correction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SUPRACOR Strong
Description: SUPRACOR algorithm with strong (130%) ablation profile. SUPRACOR is a presbyopic algorithm that consists of a pre-calculated pulse pattern combined to the refractive pattern to combine near, intermediate and distance vision correction.
Study: NCT01079312

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: infusion pump
Description: anaesthesiologist´s managed infusion of propofol 10 mg/ml at rate of 10-60ml/h during ERCP targeting to moderate sedation level

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: infusion pump for patient-controlled sedation
Description: self-administration of propofol and remifentanil mixture with zero lockout time and without dose limit and background infusion via Arcomed,Syramed AG,Switzerland self-administration pump.
Study: NCT02200770

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV placebo matched to inebilizumab.
Study: NCT01079312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: Fentanyl citrate 50 mcg/ml,solution for injection,is a narcotic analgesic.In propofol infusion group 0.05 mg of fentanyl was administered intravenously before initiation of sedation. Additional 0.05 mg boluses of fentanyl were given if nociceptive stimulus was anticipated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sedative mixture
Description: Sedative mixture was prepared by adding 5 ml of remifentanil hydrochlorid solution (50 mcg/ml)to 20 ml of propofol (10 mg/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil hydrochlorid
Description: Solution of remifentanil hydrochlorid (50 mcg/ml) was used for preparation of sedative mixture(see sedative mixture for details)
Study: NCT03704493

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Video Group
Description: A video of a group of five amateur runners running along woods and fields. The group was filmed from behind to give the patient the impression of running within the group.
Study: NCT02374229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical ablation of ganglion plexus pulmonary artery.
Description: Performed ablation zone pulmonary artery bifurcation, at 2mm proximal direction and a distal direction in the left and right branches of the pulmonary artery using the electrophysiological device Atricure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mitral valve surgery
Description: The standard procedure for mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement, depending upon the particular morphological condition of the mitral valve.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mitral valve surgery
Description: The standard procedure for mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement, depending upon the particular morphological condition of the mitral valve.
Study: NCT03709966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable monitoring device
Description: similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine
Description: Physical activity promotion supported by a kinesiologist
Study: NCT02167321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A : standard neoadjuvant chemoradiotherapy group
Description: radiation : 45Gy±5.4Gy/28Fx/5.5weeks concurrent chemoradiotherapy : 5-FU (400 mg/m2, IV bolus on D1-3, D29-31), leucovorin (20 mg/m2, IV bolus on D1-3, D29-31), preoperative capecitabine : 825 mg/m² p.o. twice daily during XRT, postoperative FL : 5-FU (400 mg/m2, IV bolus)+leucovorin (20m g/m2, IV bolus) on days 1-5 of each 28 day postoperative capecitabine : 1250 mg/m² p.o. twice daily on days 1-14 of each 21 day cycle FOLFOX : oxaliplatin 85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, leucovorin 200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, 5-FU 400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B : adjuvant FOLFOX group
Description: FOLFOX : oxaliplatin (85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), leucovorin (200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), 5-FU (400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle) postoperative irradiation(if needed) : 54Gy/30Fx/6weeks
Study: NCT00814905

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: A saline infusion after delivery (one dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ampicillin gentamicin
Description: one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery
Study: NCT01650454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 night polysomnography
Description: Polysomnography

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 night polysomnography
Description: Polysomnography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: battery of neuropsychological tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: battery of neuropsychological tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: subjective evaluation of sleep and somnolence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subjective evaluation of sleep and somnolence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subjective evaluation of sleep and somnolence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: subjective evaluation of sleep and somnolence
Study: NCT01326299

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate placebo
Description: dissolve in water and consume with meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional ingredient
Description: Dissolve in water and consume with meals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: #1 Nutritional ingredient +Fiber
Description: Dissolve in water and consume with meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: #2 Nutritional ingredient + Fiber
Description: Dissolve in water and consume with meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: #3 Nutritional ingredient + Fiber
Description: Dissolve in water and consume with meal
Study: NCT01006720

Intervention type: DRUG
Intervention: Neostigmine
Description: Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
Study: NCT03531190

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional supplement (Protein)
Description: Protein supplement as needed
Study: NCT05355038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification (dietary modification)
Description: low glycemic index diet the researcher gave detail information about (importance of LGI diet, component of food, number of meals and snake, example of food taken in breakfast, lunch, dinner and snake in between, food allowed and not allowed). After that, the researcher required from the woman to make an example of food for one day according to her income level, if correction of the content of food needed, the researcher will explain this point again.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification (physical activity)
Description: health teaching about choose between two types of exercise to be selected according to the ability of GDM women to perform : brisk walking or seated arm exercise or selected both. Brisk walking should be performed for at least half an hour three time /week, while, seated arm exercise done three time after each meal for10 minute in each time. The researcher given a detail information about both types and its importance in decreasing blood glucose level, also how to perform and what should be done in case of appearance of fatigue manifestation during exercise, and the women have choice for perform both or selected one to perform according to your health condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification( self glucose monitoring)
Description: self-glucose monitoring the researcher explain the important of monitoring blood glucose level and instruct the women about how to perform self- glucose measuring, recording way of the result in schedule and to bring this result in the next antenatal visit. The women who have digital blood glucose monitoring instructed to measure it at least 5 time/day. while, the women who didn't have digital blood glucose monitoring measure went to nearest pharmacy to measure blood glucose at least one time per day especially when the woman felt the signs and symptoms of hypo or hyperglycemia and recorded the result in paper or sent the result in whatsapp for the researcher if you have whatsapp application. In addition to give the woman instruction about sings symptoms of hypoglycemia and hyperglycemia and the proper ways for management
Study: NCT01850095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment azelaic acid (azelan)
Description: treatment for 6 months
Study: NCT01006720

Intervention type: DRUG
Intervention: Neostigmine
Description: Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)

Intervention type: DRUG
Intervention: Neostigmine
Description: Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)

Intervention type: DRUG
Intervention: Neostigmine
Description: Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)

Intervention type: DRUG
Intervention: Neostigmine
Description: Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)

Intervention type: DRUG
Intervention: Saline
Description: Saline 0.9% (Saline)
Study: NCT00574119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: spironolactone 50 mg daily for 6 months
Study: NCT01115738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prasugrel
Description: Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Loading dose administered once orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Loading dose administered once orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Loading dose administered once orally
Study: NCT04662216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing + Perisolv +Hyadent BG gels
Description: Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes), Perisolv gel will adjectively be applied to all pockets with probing depth(PD) ≥ 5 mm, which will be inserted into periodontal pockets before and during SRP (2 times). The nozzle will be placed in the pocket mesially, lingually, distally and bucally. Afterwards, all teeth will be polished and all treated pockets will be filled with hyaluronic acid gel (Hyadent BG).
Study: NCT02804061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NELIP

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NELIP
Study: NCT01363557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole brain radiotherapy
Description: External beam RT using a total dose of 30 Gy with ten daily fractions of 3.0 Gy given 5 days per week over 2 weeks + Gefitinib 250 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib (IRESSA)
Description: 250 mg/day
Study: NCT04091230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRUSbx
Description: Trans Rectal UltraSound guided Prostate Biopsy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRUSbx
Description: Trans Rectal UltraSound guided Prostate Biopsy
Study: NCT03448224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Questionnaire

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Intervention
Study: NCT01222572

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic boost

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic boost

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic boost

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT00729313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide microparticles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03269890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsule and cutaneous blocks
Description: 7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks once before surgery per side

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-intermediate cervical plexus block
Description: 15 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml once before surgery per side.
Study: NCT01293149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: ropivacaine 0.2% 0.5 ml/kg (max 20 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: clonidine 1 mcg/kg AND ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
Study: NCT04733846

Intervention type: OTHER
Intervention: data collection
Description: Collection of clinical and paraclinical data during preoperative consultation Collection of clinical and paraclinical data during post-operative consultations Tele-consultation to determine if criteria for good healing / adherence, treatment tolerance / response to questions Remote follow-up 6 and 12 months after the trauma
Study: NCT04148599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine infusion
Description: a loading dose of 1µg/kg of dexmedetomidine (precedex) made to 50 ml using normal saline will be given over 10 minutes followed by infusion of dexmedetomidine with a dose of 0.5µg/kg/hour till the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine infusion
Description: a loading dose of 1.5 mg/kg of lidocaine made to 50 ml using normal saline and given over 10 minutes followed by infusion of lidocaine with a dose of 1.5 mg/kg/hour till the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 50 ml of normal saline given over 10 minutes followed by saline infusion intraoperatively at a rate of 10 ml/hour till the end of surgery.
Study: NCT02252692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: oral administration